Concord Medical Services Holdings (CCM) Research & Development (2011 - 2025)

Concord Medical Services Holdings has reported Research & Development for 15 years, with the latest figure at -$6.7 million in Q2 2025.

• For the quarter ending Q2 2025, Research & Development rose 44.01% year-over-year to -$6.7 million; the trailing twelve-month figure through Jun 2025 stood at $8.0 million (down 76.97% YoY), and the FY2015 full-year result was $92.3 million, down 5.66% from the prior year.
• Research & Development for Q2 2025 stood at -$6.7 million, up from -$11.9 million in the prior quarter.
• The five-year high for Research & Development was $19.9 million in Q2 2021, with the low at -$11.9 million in Q2 2024.
• Historically, Research & Development has averaged $5.6 million across 5 years, with a median of $9.2 million in 2022.
• Annual changes were most pronounced in 2021 — Research & Development surged 273.95% — and 2024, when it plunged 168.56%.
• Concord Medical Services Holdings' Research & Development stood at $19.9 million in 2021, then tumbled by 54.03% to $9.2 million in 2022, then soared by 89.28% to $17.3 million in 2023, then sank by 168.56% to -$11.9 million in 2024, then surged by 44.01% to -$6.7 million in 2025.
• The last three Research & Development figures came in at -$6.7 million (Q2 2025), -$11.9 million (Q2 2024), and $17.3 million (Q2 2023), per Business Quant data.